KRW 101900.0
(-3.04%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | 60.23 Billion KRW | 1670.36% |
2022 | 3.4 Billion KRW | -89.57% |
2021 | 32.62 Billion KRW | -36.07% |
2020 | 51.02 Billion KRW | 2.76% |
2019 | 49.65 Billion KRW | -29.28% |
2018 | 70.21 Billion KRW | -39.13% |
2017 | 115.33 Billion KRW | -17.76% |
2016 | 140.25 Billion KRW | 63.08% |
2015 | 86 Billion KRW | 256.85% |
2014 | 24.1 Billion KRW | 30.27% |
2013 | 18.5 Billion KRW | 0.0% |
2012 | - KRW | 0.0% |
2011 | - KRW | 0.0% |
2010 | - KRW | -100.0% |
2009 | 1.4 Billion KRW | -43.09% |
2008 | 2.46 Billion KRW | -30.11% |
2007 | 3.52 Billion KRW | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q2 | 81.85 Billion KRW | 4.07% |
2024 Q1 | 78.65 Billion KRW | 0.0% |
2023 Q4 | - KRW | -100.0% |
2023 Q2 | 28 Billion KRW | 68.42% |
2023 Q1 | 16.62 Billion KRW | 388.63% |
2023 FY | 60.23 Billion KRW | 1670.36% |
2023 Q3 | 33.06 Billion KRW | 18.08% |
2022 Q4 | 3.4 Billion KRW | 202.43% |
2022 Q2 | 17.62 Billion KRW | -36.2% |
2022 Q3 | 1.12 Billion KRW | -93.62% |
2022 Q1 | 27.62 Billion KRW | -15.32% |
2022 FY | 3.4 Billion KRW | -89.57% |
2021 Q3 | 47.17 Billion KRW | -11.28% |
2021 FY | 32.62 Billion KRW | -36.07% |
2021 Q1 | 52.35 Billion KRW | 2.61% |
2021 Q4 | 32.62 Billion KRW | -30.85% |
2021 Q2 | 53.17 Billion KRW | 1.55% |
2020 Q3 | 67.25 Billion KRW | 49.36% |
2020 Q1 | 44.43 Billion KRW | -10.51% |
2020 Q2 | 45.02 Billion KRW | 1.32% |
2020 Q4 | 51.02 Billion KRW | -24.12% |
2020 FY | 51.02 Billion KRW | 2.76% |
2019 Q3 | 73.68 Billion KRW | -0.47% |
2019 Q1 | 70.21 Billion KRW | 0.0% |
2019 Q4 | 49.65 Billion KRW | -32.61% |
2019 FY | 49.65 Billion KRW | -29.28% |
2019 Q2 | 74.03 Billion KRW | 5.45% |
2018 Q3 | 117.28 Billion KRW | 1.69% |
2018 FY | 70.21 Billion KRW | -39.13% |
2018 Q1 | 115.33 Billion KRW | 0.0% |
2018 Q2 | 115.33 Billion KRW | 0.0% |
2018 Q4 | 70.21 Billion KRW | -40.14% |
2017 Q4 | 115.33 Billion KRW | -18.12% |
2017 FY | 115.33 Billion KRW | -17.76% |
2017 Q1 | 140.25 Billion KRW | 0.0% |
2017 Q2 | 140.86 Billion KRW | 0.44% |
2017 Q3 | 140.86 Billion KRW | 0.0% |
2016 FY | 140.25 Billion KRW | 63.08% |
2016 Q4 | 140.25 Billion KRW | -3.61% |
2016 Q3 | 145.5 Billion KRW | 5.13% |
2016 Q2 | 138.4 Billion KRW | 0.0% |
2016 Q1 | 138.4 Billion KRW | 60.93% |
2015 Q3 | 63.5 Billion KRW | 30.93% |
2015 Q2 | 48.5 Billion KRW | 64.41% |
2015 FY | 86 Billion KRW | 256.85% |
2015 Q1 | 29.5 Billion KRW | 22.41% |
2015 Q4 | 86 Billion KRW | 35.43% |
2014 Q3 | 34.1 Billion KRW | 0.0% |
2014 FY | 24.1 Billion KRW | 30.27% |
2014 Q1 | 27.5 Billion KRW | 48.65% |
2014 Q2 | 34.1 Billion KRW | 24.0% |
2014 Q4 | 24.1 Billion KRW | -29.33% |
2013 Q4 | 18.5 Billion KRW | 23.33% |
2013 Q1 | 5 Billion KRW | 0.0% |
2013 FY | 18.5 Billion KRW | 0.0% |
2013 Q2 | 5 Billion KRW | 0.0% |
2013 Q3 | 15 Billion KRW | 200.0% |
2012 Q1 | - KRW | 0.0% |
2012 FY | - KRW | 0.0% |
2012 Q4 | - KRW | 0.0% |
2012 Q3 | - KRW | 0.0% |
2012 Q2 | - KRW | 0.0% |
2011 Q1 | - KRW | 0.0% |
2011 Q2 | - KRW | 0.0% |
2011 FY | - KRW | 0.0% |
2011 Q3 | - KRW | 0.0% |
2010 Q4 | - KRW | 0.0% |
2010 Q1 | - KRW | 0.0% |
2010 Q2 | - KRW | 0.0% |
2010 FY | - KRW | -100.0% |
2010 Q3 | - KRW | 0.0% |
2009 Q2 | - KRW | 0.0% |
2009 Q1 | - KRW | 0.0% |
2009 FY | 1.4 Billion KRW | -43.09% |
2009 Q4 | - KRW | 0.0% |
2009 Q3 | - KRW | 0.0% |
2008 Q1 | - KRW | 0.0% |
2008 Q3 | - KRW | 0.0% |
2008 FY | 2.46 Billion KRW | -30.11% |
2008 Q4 | - KRW | 0.0% |
2008 Q2 | - KRW | 0.0% |
2007 Q3 | - KRW | 0.0% |
2007 Q1 | 29.94 Billion KRW | 0.0% |
2007 Q2 | - KRW | -100.0% |
2007 FY | 3.52 Billion KRW | 0.0% |
2007 Q4 | - KRW | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Yuyu Pharma, Inc. | 13.64 Billion KRW | -341.595% |
Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 70.19% |
Ildong Holdings Co., Ltd. | 29.87 Billion KRW | -101.608% |
HANDOK Inc. | 123.78 Billion KRW | 51.338% |
Kukje Pharma Co., Ltd. | 475.74 Million KRW | -12560.993% |
Dong-A ST Co., Ltd. | 161.99 Billion KRW | 62.817% |
SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -59058.386% |
Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | 26.57% |
Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -10103.765% |
Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -895.599% |
Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | -225.194% |
MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -378.646% |
Hana Pharm Co., Ltd. | 1.59 Billion KRW | -3667.328% |
Yuyu Pharma, Inc. | 13.64 Billion KRW | -341.595% |
Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -50229.685% |
REYON Pharmaceutical Co., Ltd. | 121 Billion KRW | 50.22% |
Aprogen pharmaceuticals,Inc. | 32 Billion KRW | -88.231% |
JW Holdings Corporation | 20.65 Billion KRW | -191.585% |
Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | -306.294% |
Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | -100.779% |
JW Pharmaceutical Corporation | 30 Billion KRW | -100.779% |
Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -27408.9% |
Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -10273.575% |
Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | -21.516% |
Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -1252.958% |
Yuyu Pharma, Inc. | 13.64 Billion KRW | -341.595% |
Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | -216.559% |
Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | 35.521% |
JW Pharmaceutical Corporation | 30 Billion KRW | -100.779% |
Yuhan Corporation | 60.23 Billion KRW | 0.0% |
Jeil Pharma Holdings Inc | 10.5 Billion KRW | -473.655% |
Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | -49.175% |
Suheung Co., Ltd. | 74 Billion KRW | 18.611% |
JW Pharmaceutical Corporation | 30 Billion KRW | -100.779% |
Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -1345.62% |
Korea United Pharm Inc. | 10.96 Billion KRW | -449.453% |
CKD Bio Corp. | 69.43 Billion KRW | 13.247% |
Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | -74.213% |
Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | -273.481% |
Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -19516.526% |
Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -27408.9% |
Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | 16.472% |
Boryung Corporation | 151.7 Billion KRW | 60.296% |
Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | 23.294% |
Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -895.599% |
JW Lifescience Corporation | 168 Million KRW | -35753.43% |